A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Clinical trial NCT04296890 · COMPLETED
Trial details
- NCT number
- NCT04296890
- Sponsor
- ImmunoGen, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-23
- Primary completion
- 2021-11-16
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.